The stock has a 36-month beta value of 0.78. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADVM is 13.87M, and at present, short sellers hold a 10.69% of that float. On May 14, 2025, the average trading volume of ADVM was 297.19K shares.
ADVM) stock’s latest price update
Adverum Biotechnologies Inc (NASDAQ: ADVM) has experienced a decline in its stock price by -18.27 compared to its previous closing price of 2.71. However, the company has seen a fall of -31.42% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-10 that NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ADVM’s Market Performance
ADVM’s stock has fallen by -31.42% in the past week, with a monthly drop of -35.42% and a quarterly drop of -45.04%. The volatility ratio for the week is 16.39% while the volatility levels for the last 30 days are 12.18% for Adverum Biotechnologies Inc The simple moving average for the past 20 days is -26.69% for ADVM’s stock, with a -60.50% simple moving average for the past 200 days.
Analysts’ Opinion of ADVM
Many brokerage firms have already submitted their reports for ADVM stocks, with Oppenheimer repeating the rating for ADVM by listing it as a “Outperform.” The predicted price for ADVM in the upcoming period, according to Oppenheimer is $25 based on the research report published on June 25, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $30. The rating they have provided for ADVM stocks is “Buy” according to the report published on April 30th, 2024.
Truist gave a rating of “Buy” to ADVM, setting the target price at $4 in the report published on July 07th of the previous year.
ADVM Trading at -42.57% from the 50-Day Moving Average
After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.16% of loss for the given period.
Volatility was left at 12.18%, however, over the last 30 days, the volatility rate increased by 16.39%, as shares sank -35.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.75% lower at present.
During the last 5 trading sessions, ADVM fell by -31.42%, which changed the moving average for the period of 200-days by -72.62% in comparison to the 20-day moving average, which settled at $3.02. In addition, Adverum Biotechnologies Inc saw -52.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADVM starting from Leonard Braden Michael, who purchase 20,407 shares at the price of $5.04 back on Mar 26 ’25. After this action, Leonard Braden Michael now owns 125,207 shares of Adverum Biotechnologies Inc, valued at $102,841 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Adverum Biotechnologies Inc, purchase 16,593 shares at $5.19 during a trade that took place back on Mar 27 ’25, which means that Leonard Braden Michael is holding 141,800 shares at $86,089 based on the most recent closing price.
Stock Fundamentals for ADVM
Current profitability levels for the company are sitting at:
- -150.16 for the present operating margin
- -12.49 for the gross margin
The net margin for Adverum Biotechnologies Inc stands at -130.93. The total capital return value is set at -0.96. Equity return is now at value -144.41, with -63.10 for asset returns.
Based on Adverum Biotechnologies Inc (ADVM), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01.
Currently, EBITDA for the company is -135.51 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 77.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.73.
Conclusion
To sum up, Adverum Biotechnologies Inc (ADVM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
